Colitis Associated Cancer

Ji Li, Wei-Xun Zhou, Shuang Liu, Wei-Yang Zheng, Ya-Nan Wang, Jing-Nan Li, Jose Gp Ferraz, Jia-Ming Qian, Xian-Yong Gui
BACKGROUND: Colorectal cancer (CRC) has become one of the major life-threatening complications in patients with inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD). This study aimed to explore the clinical-pathologic similarities and differences in the IBD-associated CRC (IBD-CRC) between patients in China and Canada. METHODS: Data of 78 patients with IBD-CRC retrospectively retrieved from two representative medical institutions in Beijing (China) and Calgary (Canada) over the same past 13 years, including 25 (22 UC-associated and three CD-associated) from Beijing group and 53 (32 UC-associated and 21 CD-associated) from Calgary group, were compared with regards to their clinical and pathologic characteristics...
November 12, 2019: Chinese Medical Journal
Uday N Shivaji, Louisa Jeffery, Xianyong Gui, Samuel C L Smith, Omer F Ahmad, Ayesha Akbar, Subrata Ghosh, Marietta Iacucci
Background: Drug-induced colitis is a known complication of therapies that alter the immune balance, damage the intestinal barrier or disturb intestinal microbiota. Immune checkpoint inhibitors (ICI) directed against cancer cells may result in activated T lymphocyte-induced immune-related adverse events (AEs), including immune-related colitis and hepatitis. The aim of this review article is to summarize the incidence of gastrointestinal (GI) and hepatic AEs related to ICI therapy. We have also looked at the pathogenesis of immune-mediated AEs and propose management strategies based on current available evidence...
2019: Therapeutic Advances in Gastroenterology
Takahito Takeuchi
INTRODUCTION: Studies evaluating the age-related alteration of human appendix have been reported. Although the appendix shows a degeneration of lymphoid tissues with aging, the mechanism of action remains unclear. MATERIAL AND METHODS: Surgically resected appendix tissues from patients with colon cancer, intestinal malrotation and ulcerative colitis (UC) were utilized for histological and flow cytometric analysis. RESULTS: Histological analysis showed that aging may induce steatotic changes in the appendix...
November 13, 2019: Kurume Medical Journal
Markus V Heppt, Teresa Amaral, Katharina C Kähler, Lucie Heinzerling, Jessica C Hassel, Markus Meissner, Nicole Kreuzberg, Carmen Loquai, Lydia Reinhardt, Jochen Utikal, Evelyn Dabrowski, Anja Gesierich, Claudia Pföhler, Patrick Terheyden, Kai-Martin Thoms, Lisa Zimmer, Thomas K Eigentler, Michael C Kirchberger, Henner M Stege, Friedegund Meier, Max Schlaak, Carola Berking
BACKGROUND: Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear. METHODS: Patients with metastatic or unresectable UM treated with ipilimumab in combination with a PD-1 inhibitor were collected from 16 German skin cancer centers. Patient records of 64 cases were analyzed for response, progression-free survival (PFS), overall survival (OS), and safety...
November 13, 2019: Journal for Immunotherapy of Cancer
Qun Zhao, Yun Bi, Jing Zhong, Ziting Ren, Yingxiang Liu, Junjun Jia, Mengting Yu, Yan Tan, Qiufang Zhang, Xianjun Yu
Pristimerin, a triterpenoid, has exhibited potential anti-inflammatory and anti-tumor activities. Nevertheless, the role and mechanism of pristimerin in intestinal inflammation and colon cancer require further investigation. Here, we found that pristimerin protected mice from dextran sulfate sodium (DSS)-induced colitis, restoring epithelial damage and reducing tissue inflammation and inflammatory cell infiltration. In addition, pristimerin dramatically reduced the number and size of the tumors in a azoxymethane (AOM)/DSS-induced colitis-associated colorectal cancer (CAC) model...
November 9, 2019: Toxicology and Applied Pharmacology
Qing-Qing Chai, Jiang-Yang Du, Jun Zhu, Bin Wu
Background: Immune checkpoint inhibitors (ICIs) have evolved for the treatment of solid tumors. In addition to the efficacy of ICIs for cancer, the adverse events (AEs) of ICIs are also noteworthy for gradually more extensive clinical use. Objective: To conduct a systematic review and network meta-analysis to evaluate the treatment-related AEs that occurred in clinical trials using different kinds of ICIs, to explore the differences in AEs among ICIs for treating non-small cell lung cancer (NSCLC) and melanoma, and to compare select immune-related AEs...
2019: Frontiers in Pharmacology
Lan-Lan Lin, Guo-Fu Lin, Qiong Luo, Xiang-Qi Chen
BACKGROUND: The programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors have shown encouraging merits in non-small cell lung cancer (NSCLC) patients, however, they are often related to potentially fatal immune-related adverse events (irAEs) including colitis. Considering the incidence and characteristics of immune-related colitis may have significant implications for the appropriate utilization of PD-1/PD-L1 inhibitors in clinical practice, we conduct this meta to systematically analyze the correlation between PD-1/PD-L1 inhibitors for the treatment of NSCLC and the incidence of immune-associated colitis...
November 5, 2019: International Immunopharmacology
Leokadia Bąk-Romaniszyn, Anna S Świerzko, Anna Sokołowska, Łukasz Durko, Grażyna Mierzwa, Agnieszka Szala-Poździej, Ewa Małecka-Panas, Maciej Cedzyński
Inflammatory bowel disease (IBD) refers to disorders associated with progressive inflammatory processes in the gastrointestinal system. IBD consists of two major forms, Crohn's disease (CD), and ulcerative colitis (UC). IBD became a global disease in the 21st century. Its pathogenesis is still not fully understood. Mannose-binding lectin (MBL) is a pattern-recognising molecule, involved in anti-microbial and anti-cancer immunity. It is able to opsonize microorganisms and abnormal host cells, and to initiate complement activation...
October 31, 2019: Immunobiology
Maria V Deligiorgi, Mihalis I Panayiotidis, Dimitrios T Trafalis
Over the last decade, the breakthrough of immune checkpoint inhibitors has revolutionized cancer therapeutics, an enterprise not devoid of a novel constellation of unique immune-related adverse events. In this article, we present the first two patients, one with metastatic urothelial bladder cancer and another one with inoperable non-small squamous cell lung carcinoma, with immune-related parathyroid hormone related protein (PTHrP)-mediated hypercalcemia concurrent with immune-related pneumonitis following administration of anti-PD-1 monoclonal antibody nivolumab...
November 4, 2019: International Immunopharmacology
Weidong Han, Binbin Xie, Yiran Li, Linlin Shi, Jianqin Wan, Xiaona Chen, Hangxiang Wang
Purpose: Colitis-associated colorectal cancer (CAC) poses substantial challenges for effective treatment. Currently, there is a considerable need for the development of orally bioavailable dosage forms that enable the safe and effective delivery of therapeutic drugs to local diseased lesions in the gastrointestinal tract. Experimental Design: In this study, we developed orally deliverable nanotherapeutics for the synergistic treatment of inflammatory bowel diseases (IBDs) and CAC. Water-insoluble curcumin (CUR) and 7-ethyl-10-hydroxycamptothecin (SN38), which served as anti-inflammatory and cytotoxic agents, respectively, were chemically engineered into hydrophilic mucoadhesive chitosan for the generation of chitosan-drug amphiphiles...
2019: Theranostics
Miao Li, Qing-Fan Yang, Qian Cao, Jian Tang, Yu Gao, Min Zhi, Kang Chao, Ming-Li Su, Wei-Min Huang, Yan Yi, Sui-Yan Xia, Ling-Jie Huang, Yuan Zhao, Xiao-Hong Wang, Xiao-Ying Liu, Lin Lin, Pin-Jin Hu, Xiang Gao
Background and aim: This cross-sectional study investigated the prevalence and risk factors of high-risk human papilloma virus (HPV) infection, especially types 16 and 18, and cervical neoplasia in female Inflammatory bowel disease (IBD) patients. Methods: From July 2014 to January 2017, sexually active, female, Chinese IBD patients (21-60 years) and age-matched controls underwent cervical ThinPrep cytology testing (TCT) and high-risk HPV-DNA detection, and completed questionnaires about awareness of cervical cancer and HPV...
October 2019: Gastroenterology Report
Satoshi Okada, Keisuke Hata, Takahide Shinagawa, Tatsuki Noguchi, Toshiaki Tanaka, Kazushige Kawai, Hiroaki Nozawa, Soichiro Ishihara
BACKGROUND: Major complications in patients with ulcerative colitis (UC) include UC-associated cancer (UCAC) and postoperative pouchitis. We aimed to identify SNPs associated with UCAC/high-grade dysplasia (HGD) and pouchitis. METHODS: Patients with UC who underwent ileal pouch-anal anastomosis (IPAA) with >2 years of follow-up after functioning pouches were included. Pouchoscopies were performed at least once to diagnose pouchitis according to the modified pouchitis disease activity index...
October 31, 2019: Digestion
Aalaa Fahim Abbas, Aamal Ghazi Mahdi Al-Saadi, Miaad K Alkhudhairy
OBJECTIVE: Biofilm formation has made the therapy of bacterial infections more difficult. The objective our study was assessment of pan-drug-resistant (PDR) Klebsiella oxytoca pathogenicity and virulence factors causing AAHC in patients with colorectal cancer (CRC). MATERIALS AND METHODS: Among a total of 300 healthy and 300 patients with antibiotic-associated hemorrhagic colitis (AAHC) and CRC, 200 K. oxytoca were identified during May 2015-January 2019. The virulence properties and biofilm formation among the isolates were investigated by phenotypic, PCR, and real-time PCR (RT-qPCR) techniques...
October 28, 2019: Journal of Gastrointestinal Cancer
Xiaoming Zhong, Bin Chen, Min Liu, Zhiwen Yang
The adaptor protein CARD9 plays an important role in anti-fungal immunity responses, linking detection of fungi by surface receptors to activation of the transcription factor nuclear factor κB (NF-κB). Recent studies indicate that CARD9 also plays different but vital roles during the development of colitis-associated colorectal cancer (CAC). This review summarizes the current understanding of CARD9 functions in CAC, and we discuss its potentially carcinogenic mechanisms.
December 20, 2019: Molecular Therapy Oncolytics
Chia-Jung Kuo, Chun-Ya Chen, Horng-Ren Lo, Chun-Lung Feng, Hui-Yu Wu, Mei-Zi Huang, Tung-Nan Liao, Yu-An Chen, Chih-Ho Lai
Helicobacter pylori colonizes human gastric epithelial cells and contributes to the development of several gastrointestinal disorders. Interleukin (IL)-33 is involved in various immune responses, with reported proinflammatory and anti-inflammatory effects, which may be associated with colitis and colitis-associated cancer. IL-33 induces the inflammatory cascade through its receptor, suppression of tumorigenicity-2 (ST-2). Binding of IL-33 to membrane-bound ST-2 (mST-2) recruits the IL-1 receptor accessory protein (IL-1RAcP) and activates intracellular signaling pathways...
October 21, 2019: Cells
Ken Masuda, Hirokazu Shoji, Kengo Nagashima, Shun Yamamoto, Masashi Ishikawa, Hiroshi Imazeki, Masahiko Aoki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Narikazu Boku
BACKGROUND: Recent studies have shown that immune-related adverse events (irAEs) caused by immune checkpoint inhibitors were associated with clinical benefit in patients with melanoma or lung cancer. In advanced gastric cancer (AGC) patients, there have been few reports about the correlation between irAEs and efficacy of immune checkpoint inhibitors. In this study, we retrospectively investigated the correlation between irAEs and efficacy in AGC patients treated with nivolumab. METHODS: The subjects of this study were AGC patients received nivolumab monotherapy between January 2015 and August 2018...
October 21, 2019: BMC Cancer
Meng-Ting Ren, Meng-Li Gu, Xin-Xin Zhou, Mo-Sang Yu, Hang-Hai Pan, Feng Ji, Chen-Yan Ding
BACKGROUND: Sirtuin 1 (SIRT1) is a nicotinamide adenine dinucleotide (NAD+ )-dependent protein deacetylase that is involved in various diseases, including cancers, metabolic diseases, and inflammation-associated diseases. However, the role of SIRT1 in ulcerative colitis (UC) is still confusing. AIM: To investigate the role of SIRT1 in intestinal epithelial cells (IECs) in UC and further explore the underlying mechanisms. METHODS: We developed a coculture model using macrophages and Caco-2 cells...
October 14, 2019: World Journal of Gastroenterology: WJG
Shaoping Hu, Jiahui Yuan, Jiajia Xu, Xiaomei Li, Gongye Zhang, Qiujuan Ma, Bing Zhang, Tianhui Hu, Gang Song
BACKGROUND: Mesenchymal stem cells (MSCs) can be efficiently recruited to wound, inflammatory and tumor sites to repair and regenerate tissue. However, its role in colitis and colitis associated colon cancer is still controversial. This study was designed to evaluate the role and mechanisms of inflammatory cytokines-activated-MSCs in mice colitis and colon cancer. METHODS: We selected two well-characterized pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ), to expand the inflammatory microenvironment of MSCs...
2019: American Journal of Translational Research
Samy Babai, Anne-Laure Voisin, Célia Bertin, Amandine Gouverneur, Hervé Le-Louet
BACKGROUND: The use of immune checkpoint inhibitors (ICI) in melanoma and non-small cell lung cancer patients is associated with the onset of vitiligo. However, previous studies have suggested conflicting results on the conditions of occurrence of ICI-induced vitiligo. OBJECTIVE: The aim of this study was to describe the occurrences and outcomes of several cases of ICI-induced vitiligo. METHODS: A retrospective study was carried out using the French Pharmacovigilance Database (FPD) between the beginning of the commercialization of ICI in France and 1 January 2019, selecting for analysis the vitiligo reactions of patients due to treatment with ICI...
October 19, 2019: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
Ahmed Hammad, Zhao-Hong Zheng, Yang Gao, Akhileshwar Namani, Hong-Fei Shi, Xiuwen Tang
AIMS: Colorectal cancer (CRC) is the third most common cancer worldwide. Nuclear factor erythroid 2-related factor 2 (Nrf2), a master regulator of many cytoprotective genes, plays a protective role in carcinogenesis. Recent studies have identified a specific gene-expression signature regulated by the Nrf2 pathway in lung adenocarcinoma and head-and-neck squamous cell cancer. However, the roles of Nrf2 in the development of colitis-associated colorectal cancer (CACC) have not been well characterized...
October 16, 2019: Life Sciences
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"